

PRODUCT INFORMATION

| | |
|---|--|
| Common Name | BGB-A317;BGB A317;TEVIMBRA;Tislelizumab;VDT-482;VDT 482;VDT482 |
| Conjugate | Unconjugated |
| Synonyms | PD1;PD-1;CD279;SLEB2;hPD-1;hPD-l;hSLE1 |
| Applications | N/A |
| Recommended Dilutions | N/A |
| Formulation & Reconstitution | Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution. |
| Host Species | N/A |
| IgG type | IgG4 |
| Reactivity | Human |
| Target | PD-1 |
| Uniprot ID | Q15116 |
| Description | Anti-PD-1(tislelizumab biosimilar) IgG4) mAb |
| Delivery | 3-4 weeks |
| Storage & Shipping | Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. |
| Background | Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals. |
| Usage | Research use only |
| DIMA Disclaimer | All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to ensure no IP infringement. |

